
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience is viewed positively because its semiconductor-based DNA synthesis platform lowers cost and raises throughput, addressing a structural bottleneck in synthetic biology while supporting both NGS and DNA synthesis demand. Management and channel checks point to AI-enabled orders inflecting sharply, with FY26 AI-related demand expected to reach triple-digits growth and at least about $50M versus roughly $25M in FY25, while NGS is still expected to represent a majority of revenue in FY26 and return to 20%+ growth by FQ4. The outlook is further supported by conservative guidance, 75-80% gross margin leverage, Factory of the Future capacity for more than $1B in revenue, and a clear path to Adj. EBITDA breakeven in FQ4 as revenues ramp.
Bears say
Twist Bioscience is viewed negatively because its recent Eli Lilly antibody-characterization announcement appears non-exclusive and limited in strategic value, with Lilly retaining the service revenue and competitors like Ginkgo Bioworks making similar disclosures the same morning. The company also faces a crowded life sciences tools market where integrated incumbents such as Danaher, Agilent Technologies, and Roche can bundle products and pressure pricing, making it harder for Twist to defend a premium valuation. On top of that, the investment case depends on AI-driven and NGS demand staying strong while gross margins improve and expenses stay controlled; any slowdown in customer demand, competition, or operating leverage could delay profitability and compress sentiment.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Twist Bioscience Corp (TWST) Forecast
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares